← Leaderboards
Arnon Lavie
University Of Illinois At Chicago
$5,954,044
Attributed
$6,278,747
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $752.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,278,747 · 9
VA$0 · 2
By mechanism
R01$5,334,309 · 4
R21$649,406 · 1
R56$266,973 · 1
P41$28,059 · 3
I01$0 · 2
Top collaborators
- Brian Kenneth Kay3 shared
Others in their field
Top investigators on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Randall J Bateman · Washington University$83,824,814
- Stuart L Schreiber · Harvard University (Medical School)$49,424,554
- Jay D Keasling · University Of California-Berkeley$47,558,861
- David Heimbrook · Leidos Biomedical Research, Inc.$47,513,682
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
EnzymesMalignant NeoplasmsEngineeringPharmaceutical PreparationsDesignVariantCellsCancer CellIn VivoStructureSourceToxic EffectImmunogenicSafetyNucleoside AnalogAffectCell KillingPhosphorylationProdrugsBaseGlutaminasePreventAsparaginaseClinic
Grant awards (45)
Expanding the efficacy of asparaginase to solid tumors$0
I01 · FY2025 · VA · contact PI
Expanding the efficacy of asparaginase to solid tumors$0
I01 · FY2024 · VA · contact PI
Pharmacological and toxicological testing of a novel L-asparaginase$0
I01 · FY2024 · VA · contact PI
Expanding the efficacy of asparaginase to solid tumors$0
I01 · FY2023 · VA · contact PI
Pharmacological and toxicological testing of a novel L-asparaginase$0
I01 · FY2022 · VA · contact PI
Pharmacological and toxicological testing of a novel L-asparaginase$0
I01 · FY2021 · VA · contact PI
Development of Human Asparaginase for Cancer Therapy$0
I01 · FY2020 · VA · contact PI
Pharmacological and toxicological testing of a novel L-asparaginase$0
I01 · FY2020 · VA · contact PI
Development of Human Asparaginase for Cancer Therapy$0
I01 · FY2019 · VA · contact PI
Pharmacological and toxicological testing of a novel L-asparaginase$0
I01 · FY2019 · VA · contact PI
Development of Human Asparaginase for Cancer Therapy$0
I01 · FY2018 · VA · contact PI
Development of Human Asparaginase for Cancer Therapy$0
I01 · FY2017 · VA · contact PI
Development of Human Asparaginase for Cancer Therapy$0
I01 · FY2016 · VA · contact PI
Development of Human Asparaginase for Cancer Therapy$0
I01 · FY2015 · VA · contact PI
Molecular imaging of cell-based therapeutics using an engineered human enzyme.$345,227
R01 · FY2014 · EB · contact PI
Development of Human Asparaginase for Cancer Therapy$0
I01 · FY2014 · VA · contact PI
Molecular imaging of cell-based therapeutics using an engineered human enzyme.$335,619
R01 · FY2013 · EB · contact PI
Enzyme-delivery scaffold technology for targeted cancer killing.$186,663
R21 · FY2013 · CA · contact PI
Development of Human Asparaginase for Cancer Therapy$0
I01 · FY2013 · VA · contact PI
Molecular imaging of cell-based therapeutics using an engineered human enzyme.$355,050
R01 · FY2012 · EB · contact PI
Enzyme-delivery scaffold technology for targeted cancer killing.$231,674
R21 · FY2012 · CA · contact PI
Molecular imaging of cell-based therapeutics using an engineered human enzyme.$368,325
R01 · FY2011 · EB · contact PI
Enzyme-delivery scaffold technology for targeted cancer killing.$231,069
R21 · FY2011 · CA · contact PI
Structure/function studies of nucleoside analog activating enzymes$266,973
R56 · FY2009 · CA · contact PI
Enhancing the efficacy of nucleoside analogs$230,610
R01 · FY2009 · CA · contact PI
Structural Biology of Enzymes Activating Prodrugs$250,043
R01 · FY2008 · AI · contact PI
Enhancing the efficacy of nucleoside analogs$230,609
R01 · FY2008 · CA · contact PI
Structural Biology of Enzymes Activating Prodrugs$254,885
R01 · FY2007 · AI · contact PI
Enhancing the efficacy of nucleoside analogs$232,210
R01 · FY2007 · CA · contact PI
Structural Biology of Enzymes Activating Prodrugs$262,498
R01 · FY2006 · AI · contact PI
Enhancing the efficacy of nucleoside analogs$239,146
R01 · FY2006 · CA · contact PI
Design of Enzymes Mediating Anti-Cancer Drug Activation$273,979
R01 · FY2005 · CA
Structural Biology of Enzymes Activating Prodrugs$233,280
R01 · FY2005 · AI
Enhancing the efficacy of nucleoside analogs$232,615
R01 · FY2005 · CA
STRUCTURE OF HTK1$12,722
P41 · FY2005 · RR
Design of Enzymes Mediating Anti-Cancer Drug Activation$273,979
R01 · FY2004 · CA
STRUCTURAL STUDIES: NUCLEOSIDE ANALOG ACTIVATING KINASES$10,357
P41 · FY2004 · RR
STRUCTURE OF HTK1$2,490
P41 · FY2004 · RR
TK1$2,490
P41 · FY2004 · RR
Design of Enzymes Mediating Anti-Cancer Drug Activation$268,392
R01 · FY2003 · CA
STRUCTURAL BIOLOGY OF ENZYMES ACTIVATING PRODRUGS$234,344
R01 · FY2003 · AI
Design of Enzymes Mediating Anti-Cancer Drug Activation$258,449
R01 · FY2002 · CA
STRUCTURAL BIOLOGY OF ENZYMES ACTIVATING PRODRUGS$194,838
R01 · FY2002 · AI
STRUCTURAL BIOLOGY OF ENZYMES ACTIVATING PRODRUGS$40,373
R01 · FY2002 · AI
STRUCTURAL BIOLOGY OF ENZYMES ACTIVATING PRODRUGS$219,838
R01 · FY2001 · AI